Clinical Trials · NCT03167411
Bexagliflozin Drug/Drug Interaction Study With Exenatide Injection
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Theracos
- Enrollment
- 20
- Start date
- May 2017
- Locations
- 1 site, United States
- Primary endpoint
- Cmax (Maximum Observed Plasma Concentration)